FOTIVDA (tivozanib), FDA Approved for Treatment of Relapsed/Refractory Advanced Renal Cell Carcinoma, Available at Biologics by McKesson

CARY, N.C., March 12, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by AVEO Oncology as a specialty pharmacy provider for FOTIVDA® (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal ...
Source: McKesson News - Category: Information Technology Source Type: news